Story perspectives

Trump's AstraZeneca Deal Promises Drug Price Cuts for Low-Income Americans

10/10/2025

Summary

Story summary

President Donald Trump is set to announce a drug pricing agreement with AstraZeneca aimed at reducing costs for low-income Americans.
The move follows a similar deal with Pfizer that included a most-favored-nation pricing model.
AstraZeneca will invest $50 billion in United States manufacturing and research.
Critics question the transparency and the actual benefits for consumers.
The White House event will take place with AstraZeneca's chief executive officer present.

History

Historical Context

The Drug Price Control Act of 2007 aimed to regulate pharmaceutical pricing in the U.S., addressing rising drug costs that disproportionately affected low-income Americans. This legislation followed years of unregulated pricing, exacerbated by Medicare Part D's restrictions on price negotiations. Recent agreements, like that between President Trump and AstraZeneca, continue this trend, potentially reshaping drug pricing strategies and increasing scrutiny on pharmaceutical companies.

1 of 2

Story summary

President Donald Trump is set to announce a drug pricing agreement with AstraZeneca aimed at reducing costs for low-income Americans.
The move follows a similar deal with Pfizer that included a most-favored-nation pricing model.
AstraZeneca will invest $50 billion in United States manufacturing and research.
Critics question the transparency and the actual benefits for consumers.
The White House event will take place with AstraZeneca's chief executive officer present.

1 / 2